Citius Pharmaceuticals is trading 5.1% up today at $0.63, extending its rebound as major U.S. indices rally more than 1.5%.
- The stock continues to recover following last week's LYMPHIR commercialization rally and subsequent profit-taking.
- Today's move is largely attributed to strong risk-on sentiment across the market, which is providing a tailwind for small-cap biotech names.
- No new company-specific headlines have been released today, suggesting the price action is primarily driven by broader market strength.